Novartis Bioventures Ltd has bought stock on 4 days since Apr 2016
Former 10% Owner at Akouos, Inc., and 5 other companies
SEC CIK 0001297709 · Filings on SEC.gov ↗
Novartis Bioventures Ltd's record
3 months after each buy, from the first price a copier could get.
No buys have 3 months of prices yet. A record shows here at 3.
Companies
Every filing
37 filings since Apr 2016, newest first
Akouos, Inc.
Former 10% Owner
Galera Therapeutics, Inc.
Former 10% Owner
Galera Therapeutics, Inc.
10% owner
Galera Therapeutics, Inc.
10% owner
Galera Therapeutics, Inc.
10% owner
Galera Therapeutics, Inc.
10% owner
Galera Therapeutics, Inc.
10% owner
Aerpio Pharmaceuticals, Inc.
10% owner
Aerpio Pharmaceuticals, Inc.
10% owner
Aerpio Pharmaceuticals, Inc.
10% owner
Aerpio Pharmaceuticals, Inc.
10% owner
Aerpio Pharmaceuticals, Inc.
10% owner
Aerpio Pharmaceuticals, Inc.
10% owner
Aileron Therapeutics Inc
10% owner
Aerpio Pharmaceuticals, Inc.
10% owner
Aileron Therapeutics Inc
10% owner
Aileron Therapeutics Inc
10% owner
Aileron Therapeutics Inc
10% owner
Aileron Therapeutics Inc
10% owner
Aileron Therapeutics Inc
10% owner
Aileron Therapeutics Inc
10% owner
Aileron Therapeutics Inc
10% owner
Aileron Therapeutics Inc
10% owner
Aeglea Biotherapeutics, Inc.
10% owner
Aeglea Biotherapeutics, Inc.
10% owner
Aeglea Biotherapeutics, Inc.
10% owner
Aileron Therapeutics Inc
10% owner
Ra Pharmaceuticals, Inc.
10% owner
Ra Pharmaceuticals, Inc.
10% owner
Ra Pharmaceuticals, Inc.
10% owner
Ra Pharmaceuticals, Inc.
10% owner
Ra Pharmaceuticals, Inc.
10% owner
Ra Pharmaceuticals, Inc.
10% owner
Ra Pharmaceuticals, Inc.
10% owner
Ra Pharmaceuticals, Inc.
10% owner
Ra Pharmaceuticals, Inc.
10% owner
Aeglea Biotherapeutics, Inc.
10% owner
About Novartis Bioventures Ltd
Novartis Bioventures Ltd is a company and an indirect wholly owned subsidiary of Novartis AG, organized under the laws of Switzerland.( It is part of the broader Novartis ecosystem, an innovative medicines company headquartered in Basel that focuses on therapeutic areas including oncology, immunology, and cardio-renal-metabolic disease.(
In practice, Novartis Bioventures Ltd functions as a corporate investment vehicle connected to Novartis’s life-sciences strategy. The Novartis Venture Fund states that it invests in biotechnology and biopharmaceutical therapeutics addressing unmet patient needs, and notes that its team has backgrounds in science and business development.( Novartis Bioventures Ltd was reported as a former 10% owner of Akouos, Inc. (AKUS), reflecting its role as a corporate insider/investor rather than an individual executive.(
Written by Perplexity from public sources.
Filings come from SEC EDGAR. Not investment advice.